Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2017

Open Access 01-12-2017 | Review

Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation

Authors: John W. Frew, Mark Davidson, Dedee F. Murrell

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Login to get access

Abstract

Background

Health Related Quality of Life (HR-QoL) Patient reported outcome measures (PROMs) have high utility in evaluation of new interventions in genodermatoses, however inconsistent standards of development and validation have hampered widespread acceptance and adoption.

Objectives

To identify all published HR-QoL PROMs in genodermatoses and critically evaluate their development and measurement properties.

Methods

This systematic review was registered with PROSPERO (CRD42016053301). Ovid Medline, Embase and PsycINFO databases were utilised for literature review using predefined inclusion and exclusion criteria. PROM development was assessed using the COSMIN Checklist and measurement properties were assessed against quality criteria for measurement properties of health standard questionnaires.

Results

15 HRQoL PROMs in genodermatoses were identified. Major areas of deficiency in development were internal consistency, reliability and structural validity. No PROM satisfied measurement property standards for agreement, responsiveness or floor and ceiling effects. Four PROMs included Minimal Important Change scores for interpretability. Issues regarding the generalisability of the evaluated PROMs in culturally diverse and paediatric populations remain unresolved.

Conclusions

The overall standards of development and measurement properties in PROMs in genodermatoses is fair, despite no single instrument meeting all requirements. None are perfectly validated according to COSMIN criteria but seven of the fifteen PROMs may be appropriate pending further validation. The development of culturally appropriate and child-specific variants of PROMs should be a priority in order to increase the utility of patient based outcome measures in genodermatoses in various patient populations.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Both H, Assink-Bot ML, Busschbach J, Nijsten T Critical Review of Generic and Dermatology-Specific Health Related Quality of Life Instruments J Invest Dermatol 2007;127;2726–2739.
4.
5.
Nijsten T. Dermatology life quality index: time to move forward. J Invest Dermatol. 2012;132:11–3.CrossRefPubMed
6.
Weldring T, Smith SMS. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61–8.PubMedPubMedCentral
7.
Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Quality of Life Research. 2010;19:539–49.CrossRefPubMedPubMedCentral
8.
Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2011;21(4):651-7.
9.
Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34–42.CrossRefPubMed
10.
Heinl D, Prinsen CA, Deckert S, et al. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy. 2016;71:358–70.CrossRefPubMed
11.
12.
Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Brit J Dermatol. 2009;161:1323–30.CrossRef
13.
Dreyfus I, Taieb C, Barabarot S, et al. IQoL-32: a new ichthyosis-specific measure of quality of life. JAMA Dermatol. 2013;69:82–7.CrossRef
14.
Dufrense H, Hadj-Rabia S, Meni C, et al. Family burden in inherited ichthyosis: creation of a specific questionnaire. Orphanet Journal of Rare Diseases. 2013;8:28.CrossRef
15.
Fu T, Leachman SA, Wilson NJ, et al. Genotype-phenotype correlations among Pachyonychia Congenita patients with K16 mutations. J Invest Dermatol. 2011;131:1025–8.CrossRefPubMed
16.
Shah S, Boen M, Kenner-Bell B, et al. Pachyonychia Congenita in pediatric patients natural history features and impact. JAMA Dermatol. 2014;150:146–53.CrossRefPubMed
17.
Abbas M, Schwartz ME, Smith FJD, McLean WHI. PCQoL: a quality of life assessment measure for Pachyonychia Congenita. J Cutan Med Surg. 2015;19:57–65.CrossRefPubMed
18.
Dodiuk-Gad R, Cohen-Barak E, Ziv M, et al. Health related quality of life among Darier disease patients. J Eur Acad Dermatol Venereol. 2013;27:51–6.CrossRefPubMed
19.
Hornigold RE, Golding JF, Leschziner G, et al. The NFTI-QOL: a disease-specific quality of life questionnaire for Neurofibromatosis 2 J. Surg Neurol. 2012;73:104–11.CrossRef
20.
Ingrand I, Ingrand P, Gilbert-Dussardier B, et al. Altered quality of life in Rendu-Osler-weber disease related to recurrent epistaxis. Rhinology. 2011;49:155–62.PubMed
21.
Loaec M, Moriniere S, Hitier M, et al. Psychosocial quality of life in hereditary haemorrhagic telangiectasia patients. Rhinology. 2011;49:164–7.PubMed
22.
Prior N, Ramor E, Perez-Fernandez E. Validation of an international quality of life questionnaire for hereditary angioedema. Allergy. 2013;68:105–14.CrossRef
23.
Bonner N, Abetz-Webb L, Renault L, et al. Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. Health Qual Life Outcomes. 2015;13:92.CrossRefPubMedPubMedCentral
24.
Dufrense H, Hadj-Rabia S, Taieb C, Bodemer C. Development and validation of an epidermolysis bullosa family/parental burden score. Br J Dermatol. 2015;173:1405–10.CrossRef
25.
Ramaswami U, Stull DE, Parini R, et al. Measuring patient experiences in Fabry disease: validation of the Fabry specific pediatric health and pain questionnaire (FPHPQ). Health Qual Life Outcomes. 2012;10:116.CrossRefPubMedPubMedCentral
26.
Mathias SD, Chren MM, Colwell HH, et al. Assessing health-related quality of life for advances basal cell carcinoma and basal cell carcinoma nevus syndrome. Development of the first disease-specific patient reported outcome questionnaires. JAMA Dermatol. 2014;150:169–76.CrossRefPubMed
27.
Mathias SD, Chren MM, Crosby RD, et al. Reliability and validity of the advanced basal cell carcinoma index (aBCCdex). Br J Dermatol. 2015;173:713–9.CrossRefPubMed
28.
Woo A, Sadana A, Mauger DT, et al. Psychosocial impact of Peutz-Jeghers syndrome. Familial Cancer. 2009;8:59–65.CrossRefPubMed
29.
Lundin K, Stillesjö F, Nyberg G, Rask-Andersen H. Self-reported benefit, sound perception, and quality-of-life in patients with auditory brainstem implants (ABIs). Acta Otolaryngol. 2016;136:62–7.CrossRefPubMed
30.
31.
Shovlin CL, Gilson C, Busbridge M, et al. Can iron treatments aggravate epistaxis in some patients with hereditary hemorrhagic telangiectasia. Laryngoscope. 2016;126:2468–74.CrossRefPubMedPubMedCentral
32.
Chamali B, Finnamore H, Manning R, et al. Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study. Intractable Rare Dis Res. 2016;5:109–13.CrossRefPubMedPubMedCentral
33.
Ramakrishnan Y, Iqbal IZ, Puvanendran M, et al. A postal survey of hereditary hemorrhagic telangectasia in the northeast of England. Allergy Rhinol. 2015;6:20–7.CrossRef
34.
Yuen WY, Frew JW, Veerman K, van den Heuvel ER, Murrell DF, Jonkman MF. Health-related quality of life in epidermolysis bullosa: validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. Acta Derm Venereol. 2014;94:442–7.CrossRefPubMed
35.
Frew JW, Cepda Valdes R, Fortuna G, Murrell DF, Salas-Alanis J. Measuring quality of life in epidermolysis bullosa in Mexico: cross-cultural validation of the Hispanic version of the quality of life in epidermolysis bullosa questionnaire. J Am Acad Dermatol. 2013;69:652–3.CrossRefPubMed
36.
Cestari T, Prati C, Menegon DB, et al. Translation, cross-cultural adaptation and validation of the quality of life evaluation in epidermolysis bullosa instrument in Brazilian Portuguese. Int J Dermatol. 2016;55:e94–9.CrossRefPubMed
37.
38.
Venugopal SS, Intong LR, Cohn HI, Mather-Hillon J, Murrell DF. Responsiveness of non-Herlitz junctional epidermolysis bullosa to topical gentian violet. Int J Dermatol. 2010;49:1282–5.CrossRefPubMed
39.
Venugopal SS, Yan W, Frew JW, et al. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013;69:898–908.CrossRefPubMed
40.
Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess. 2003;80:99–103.CrossRefPubMed
41.
Sousa VD, Rojjanasrirat W. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. J Eval Clin Pract. 2011;17:268–74.CrossRefPubMed
42.
Villalonga-Olives E, Kawachi I, Almansa J, et al. Pediatric health-related quality of life: a structural equation modeling approach. PLoS One. 2014;9:e113166.CrossRefPubMedPubMedCentral
43.
Creemens J, Eiser C, Blades M Factors influencing agreement between child self-report and parent proxy-reports on the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scales Health and Qual Life Outcomes 2006;4:58.
44.
Metadata
Title
Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation
Authors
John W. Frew
Mark Davidson
Dedee F. Murrell
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-017-0739-5

Other articles of this Issue 1/2017

Orphanet Journal of Rare Diseases 1/2017 Go to the issue

Research

Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency

Research

Spinocerebellar ataxia type 29 due to mutations in ITPR1: a case series and review of this emerging congenital ataxia

Research

Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 – 2015

Position statement

A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients

Letter to the Editor

The work experience of a patient affected by Williams Syndrome: a pilot project at the Bambino Gesù Children’s Hospital

Research

Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions